Abstract
Background: Fine needle aspiration cytology (FNAC) is an important screening test for thyroid lesions. The Bethesda system for reporting thyroid cytopathology 2016 (TBSRTC) was revised by International Congress of cytology in Yokohama, Japan which is a standardized category-based reporting system of FNA specimens. There are six categories each of which predicts malignancy risk and recommends clinical management. Aim of this study was to analyze the diagnostic utility of Bethesda system in reporting of thyroid FNAC. Method: In an institution based cross sectional study of FNAC done on 410 patients from 2017 to 2019 presenting with thyroid lesion were examined and categorized as per TBSRTC. Results: The distribution of patients in the six categories was 4.63% were Category I (nondiagnostic), 90.0% Category II (benign), 0.73% were Category III (atypia of undetermined significance), 2.44% were Category IV (suspicious for follicular neoplasm), 0.49% were Category V (suspicious for malignancy), and 1.71% were Category VI (malignant). Conclusion: The Bethesda system is standardized system of reporting thyroid cytopathology; therefore, prompts the recommended clinical management of that category. These data extend the utility of TBS classification by fostering an improved understanding of the risk posed by any confirmed malignancy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Clinical and Diagnostic Pathology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
